// App-Quantinova.ai

PSY04 : Effect of Nabiximols Cannabinoid Oromucosal Spray on Depressive Symptoms, Suicidality, and Cognition in Patients with Multiple Sclerosis (MS)

Researchers

Presenter

  • John DeLuca

Principal Investigators

  • Dawn Langdon

  • Joris Berwaerts

  • Joanne Wagner

Medical Centers

  • Royal Holloway University of London

  • Kessler Foundation

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

  • Depression

Biomarkers

  • N/A

Drug/Treatment

  • Tetrahydrocannabinol

  • Cannabidiol

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved